CA2549463A1 - Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90 - Google Patents

Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90 Download PDF

Info

Publication number
CA2549463A1
CA2549463A1 CA002549463A CA2549463A CA2549463A1 CA 2549463 A1 CA2549463 A1 CA 2549463A1 CA 002549463 A CA002549463 A CA 002549463A CA 2549463 A CA2549463 A CA 2549463A CA 2549463 A1 CA2549463 A1 CA 2549463A1
Authority
CA
Canada
Prior art keywords
hsp90
composition
cells
compound
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002549463A
Other languages
English (en)
Inventor
Adeela Kamal
Francis J. Burrows
Lin Zhang
Marcus F. Boehm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Conforma Therapeutics Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2002/039993 external-priority patent/WO2003050295A2/fr
Application filed by Individual filed Critical Individual
Publication of CA2549463A1 publication Critical patent/CA2549463A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des composés cytotoxiques et des agents d'imagerie de diagnostic comprenant des ligands HSP90, ainsi que leurs méthodes d'utilisation.
CA002549463A 2002-12-12 2003-06-12 Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90 Abandoned CA2549463A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2002/039993 WO2003050295A2 (fr) 2001-12-12 2002-12-12 Essais et mises en oeuvre permettant de determiner et de moduler une activite de liaison hsp90
USPCT/US02/39993 2002-12-12
PCT/US2003/018776 WO2004054624A1 (fr) 2002-12-12 2003-06-12 Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90

Publications (1)

Publication Number Publication Date
CA2549463A1 true CA2549463A1 (fr) 2004-07-01

Family

ID=32592278

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002549463A Abandoned CA2549463A1 (fr) 2002-12-12 2003-06-12 Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90

Country Status (4)

Country Link
EP (1) EP1581261A4 (fr)
AU (1) AU2003303058A1 (fr)
CA (1) CA2549463A1 (fr)
WO (1) WO2004054624A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
WO2004018478A2 (fr) 2002-08-23 2004-03-04 Sloan-Kettering Institute For Cancer Research Synthese d'epothilones, leurs intermediaires, leurs analogues et leurs utilisations
US20050020556A1 (en) * 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
GB0526615D0 (en) * 2005-12-30 2006-02-08 Novartis Ag Organic compounds
GB0603880D0 (en) * 2006-02-27 2006-04-05 Novartis Ag Organic compounds
CN100519536C (zh) * 2006-03-21 2009-07-29 中国医学科学院医药生物技术研究所 一组连有核苷碱基的格尔德霉素衍生物
CN101854955B (zh) 2007-09-10 2012-07-18 马萨诸塞大学 靶向线粒体的抗肿瘤剂
US20110270151A1 (en) * 2008-09-08 2011-11-03 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
AU2014318826B2 (en) 2013-09-10 2019-10-10 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015066053A2 (fr) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Thérapies ciblées
EP3099332A4 (fr) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Agents thérapeutiques cibles
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
JP2020524154A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬
EP3641782A4 (fr) 2017-06-20 2021-03-24 Madrigal Pharmaceuticals, Inc. Thérapies combinées comprenant des thérapeutiques ciblées

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2338000C (fr) * 1998-07-17 2009-12-15 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives 4-thiomaleimidiques solubles dans l'eau et methodes pour les produire
JP2005510534A (ja) * 2001-11-21 2005-04-21 アクティブバイオティクス インコーポレイティッド 標的化治療薬およびその使用

Also Published As

Publication number Publication date
EP1581261A1 (fr) 2005-10-05
EP1581261A4 (fr) 2009-10-21
AU2003303058A1 (en) 2004-07-09
WO2004054624A1 (fr) 2004-07-01

Similar Documents

Publication Publication Date Title
AU2002364566B2 (en) Assays and implements for determining and modulating HSP90 binding activity
CA2549463A1 (fr) Cytotoxines et agents d'imagerie de diagnostic comprenant des ligands hsp90
EP1472230B1 (fr) Ansamycines a proprietes pharmacologiques et biologiques ameliorees
US7553979B2 (en) HSP90-inhibiting zearalanol compounds and methods of producing and using same
US8518897B2 (en) Method of treatment for cancers associated with elevated HER2 levels
EP2879675B1 (fr) Composés et procédés pour le ciblage de hsp90
CN114315754B (zh) 一种异羟肟酸类化合物及其用途
Sabry et al. New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity
US20080280878A1 (en) Methods and Compositions for Treating Chronic Lymphocytic Leukemia
You et al. Design, synthesis and biological evaluation of N-arylsulfonyl carbazoles as novel anticancer agents
US20060251574A1 (en) Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
Abdelgawad et al. Phthalazone tethered 1, 2, 3-triazole conjugates: In silico molecular docking studies, synthesis, in vitro antiproliferative, and kinase inhibitory activities
Ghorab et al. Design, synthesis and molecular modeling study of certain quinazolinone derivatives targeting poly (ADP-ribose) polymerase 1 (PARP-1) enzyme as anti-breast cancer and radio-sensitizers
Xing et al. Discovery of Novel Tetrahydro-β-carboline Containing Aminopeptidase N Inhibitors as Cancer Chemosensitizers
CA2439143A1 (fr) Combi-molecules possedant des proprietes inhibitrices de transduction de signaux et d'endommagement de l'adn
Lei et al. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments
WO2006085330A2 (fr) Utilisation d'inhibiteurs de la tyrosine kinase pour le traitement de leiomyomes
Tan et al. Design, synthesis and biological evaluation of novel dihydroquinolin-4 (1H)-one derivatives as novel tubulin polymerization inhibitors
WO2021207352A1 (fr) Compositions et procédés pour le traitement de cancers résistant aux médicaments anticancéreux
Mohammed et al. Synthesis and biological evaluation of 4H-benzo [e][1, 3] oxazin-4-ones analogues of TGX-221 as inhibitors of PI3Kβ
FRIDÉN-SAXIN Design, Synthesis, and Evaluation of Functionalized Chromaffin-4-one and Chromone Derivatives
WO2009067697A1 (fr) Composés thérapeutiques

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead